| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Animal Models |
,¶,||
From the Departments of Microbiology and Immunology, * Anatomy and Cell Biology, and Medicine, ¶ the Walther Oncology Center, and the Laboratory Animal Resource Center, Indiana University School of Medicine; and the Walther Cancer Institute, || Indianapolis, Indiana
Abstract
The human immunodeficiency virus type 1 (HIV-1) Tat protein is a key pathogenic factor in a variety of acquired immune deficiency syndrome (AIDS)-associated disorders. A number of studies have documented the neurotoxic property of Tat protein, and Tat has therefore been proposed to contribute to AIDS-associated neurological diseases. Nevertheless, the bulk of these studies are performed in in vitro neuronal cultures without taking into account the intricate cell-cell interaction in the brain, or by injection of recombinant Tat protein into the brain, which may cause secondary stress or damage to the brain. To gain a better understanding of the roles of Tat protein in HIV-1 neuropathogenesis, we attempted to establish a transgenic mouse model in which Tat expression was regulated by both the astrocyte-specific glial fibrillary acidic protein promoter and a doxycycline (Dox)-inducible promoter. In the present study, we characterized the phenotypic and neuropathogenic features of these mice. Both in vitro and in vivo assays confirmed that Tat expression occurred exclusively in astrocytes and was Dox-dependent. Tat expression in the brain caused failure to thrive, hunched gesture, tremor, ataxia, and slow cognitive and motor movement, seizures, and premature death. Neuropathologies of these mice were characterized by breakdown of cerebellum and cortex, brain edema, astrocytosis, degeneration of neuronal dendrites, neuronal apoptosis, and increased infiltration of activated monocytes and T lymphocytes. These results together demonstrate that Tat expression in the absence of HIV-1 infection is sufficient to cause neuropathologies similar to most of those noted in the brain of AIDS patients, and provide the first evidence in the context of a whole organism to support a critical role of Tat protein in HIV-1 neuropathogenesis. More importantly, our data suggest that the Dox inducible, brain-targeted Tat transgenic mice offer an in vivo model for delineating the molecular mechanisms of Tat neurotoxicity and for developing therapeutic strategies for treating HIV-associated neurological disorders.
Related articles in Am J Pathol:
This article has been cited by other articles:
 |
|
 |
|
  V. Musante, M. Summa, E. Neri, A. Puliti, T. T. Godowicz, P. Severi, G. Battaglia, M. Raiteri, and A. Pittaluga The HIV-1 Viral Protein Tat Increases Glutamate and Decreases GABA Exocytosis from Human and Mouse Neocortical Nerve Endings Cereb Cortex, December 24, 2009; (2009) bhp274v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Kim, K. A. Martemyanov, and S. A. Thayer Human Immunodeficiency Virus Protein Tat Induces Synapse Loss via a Reversible Process That Is Distinct from Cell Death J. Neurosci., November 26, 2008; 28(48): 12604 - 12613. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sun, J. H. Zheng, M. Zhao, S. Lee, and H. Goldstein Increased In Vivo Activation of Microglia and Astrocytes in the Brains of Mice Transgenic for an Infectious R5 Human Immunodeficiency Virus Type 1 Provirus and for CD4-Specific Expression of Human Cyclin T1 in Response to Stimulation by Lipopolysaccharides J. Virol., June 1, 2008; 82(11): 5562 - 5572. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Blanco, S. Alvarez, M. Fresno, and M. A. Munoz-Fernandez Extracellular HIV-Tat Induces Cyclooxygenase-2 in Glial Cells through Activation of Nuclear Factor of Activated T Cells J. Immunol., January 1, 2008; 180(1): 530 - 540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Zou, B. O. Kim, B. Y. Zhou, Y. Liu, A. Messing, and J. J. He Protection against Human Immunodeficiency Virus Type 1 Tat Neurotoxicity by Ginkgo biloba Extract EGb 761 Involving Glial Fibrillary Acidic Protein Am. J. Pathol., December 1, 2007; 171(6): 1923 - 1935. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Chandrasekaran, J. L. Hazelton, Y. Wang, G. Fiskum, and T. Kristian Neuron-Specific Conditional Expression of a Mitochondrially Targeted Fluorescent Protein in Mice J. Neurosci., December 20, 2006; 26(51): 13123 - 13127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Clark III, C. S. Sampair, P. Kofuji, A. Nath, and Jian. M. Ding HIV protein, transactivator of transcription, alters circadian rhythms through the light entrainment pathway Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2005; 289(3): R656 - R662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. K. Avraham, S. Jiang, T.-H. Lee, O. Prakash, and S. Avraham HIV-1 Tat-Mediated Effects on Focal Adhesion Assembly and Permeability in Brain Microvascular Endothelial Cells J. Immunol., November 15, 2004; 173(10): 6228 - 6233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Liu, H. Liu, B. O. Kim, V. H. Gattone, J. Li, A. Nath, J. Blum, and J. J. He CD4-Independent Infection of Astrocytes by Human Immunodeficiency Virus Type 1: Requirement for the Human Mannose Receptor J. Virol., April 15, 2004; 78(8): 4120 - 4133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. O. Kim, Y. Liu, B. Y. Zhou, and J. J. He Induction of C Chemokine XCL1 (Lymphotactin/Single C Motif-1{alpha}/Activation-Induced, T Cell-Derived and Chemokine-Related Cytokine) Expression by HIV-1 Tat Protein J. Immunol., February 1, 2004; 172(3): 1888 - 1895. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
